Dr. Wong Discusses the FDA Approval of Elotuzumab Triplet in Myeloma

Sandy Wong, MD
Published: Tuesday, Nov 06, 2018



Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses the FDA approval of elotuzumab (Empliciti) for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma.

This triplet is indicated for use in patients following 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor (PI). The approval was based on findings from the phase II ELOQUENT-3 trial, in which the addition of elotuzumab to pomalidomide and dexamethasone reduced the risk of disease progression or death by 46% compared with pomalidomide and dexamethasone alone.

Additionally, median progression-free survival was 10.3 months (95% CI, 5.6–not estimable) with the elotuzumab combination compared with 4.7 months (95% CI, 2.8-7.2) with pomalidomide plus dexamethasone (HR, 0.54; 95% CI, 0.34-0.86; P = .0078). Additionally, the objective response rate was 53% (95% CI, 40%-66%) with the elotuzumab triplet compared with 26% (95% CI, 16%-40%) in the control arm (odds ratio, 3.25; 95% CI, 1.49-7.11; P = .0029).
SELECTED
LANGUAGE


Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses the FDA approval of elotuzumab (Empliciti) for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma.

This triplet is indicated for use in patients following 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor (PI). The approval was based on findings from the phase II ELOQUENT-3 trial, in which the addition of elotuzumab to pomalidomide and dexamethasone reduced the risk of disease progression or death by 46% compared with pomalidomide and dexamethasone alone.

Additionally, median progression-free survival was 10.3 months (95% CI, 5.6–not estimable) with the elotuzumab combination compared with 4.7 months (95% CI, 2.8-7.2) with pomalidomide plus dexamethasone (HR, 0.54; 95% CI, 0.34-0.86; P = .0078). Additionally, the objective response rate was 53% (95% CI, 40%-66%) with the elotuzumab triplet compared with 26% (95% CI, 16%-40%) in the control arm (odds ratio, 3.25; 95% CI, 1.49-7.11; P = .0029).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x